Centro Regional Of Investigaciones Biomedicas Crib
Centro Regional Of Investigaciones Biomedicas Crib
de la Cruz-Morcillo M.A.,Centro Regional Of Investigaciones Biomedicas Crib |
Garcia-Cano J.,Centro Regional Of Investigaciones Biomedicas Crib |
Arias-Gonzalez L.,Centro Regional Of Investigaciones Biomedicas Crib |
Garcia-Gil E.,Centro Regional Of Investigaciones Biomedicas Crib |
And 10 more authors.
Cancer Letters | Year: 2013
The p38 Mitogen Activated Protein Kinase (MAPK) signaling pathway has become a major player in the response to DNA-damage. A growing body of evidences has been relating this signaling pathway to the cellular response to ionizing radiation (IR), suggesting a role in radioresistance. Here, we study the implication of this signaling pathway in the response to IR in terms of radioresistance. To this end we used 10 different cell lines derived from several types of tumors (colorectal, non-small cell lung cancer -NSCLC-, renal and glioblastoma). Although p38 MAPK is transiently activated by IR, our data, obtained by genetic and chemical approaches, showed that this signaling pathway is not implicated in cellular viability after IR exposure. Indeed, down-modulation of this signaling pathway promotes a mild radiosensitivity depending on the cell line. However, it is remarkable that lack of p38 MAPK α abrogates the radiosensitizing effect of 5-Fluorouracil (5-FU) in HCT116 cell line, supporting the role of this MAPK in the radiosensitizing action of 5-FU. © 2013 Elsevier Ireland Ltd.
Salinas-Sanchez A.S.,Complejo Hospitalario Universitario Of Albacete |
Gimenez-Bachs J.M.,Complejo Hospitalario Universitario Of Albacete |
Serrano-Oviedo L.,Complejo Hospitalario Universitario Of Albacete |
Nam Cha S.,Complejo Hospitalario Universitario Of Albacete |
Sanchez-Prieto R.,Centro Regional Of Investigaciones Biomedicas Crib
Actas Urologicas Espanolas | Year: 2012
Context: Only on the basis of the involvement of the vhl suppressor gene in the cases of renal cell carcinomas (RCC), the involvement of the signaling pathway between the pVHL and the Hypoxia inducible factor 1, alpha (HIF-1α) has been evaluated because of the need to find new diagnostic and prognostic and response to drugs markers. Evidence synthesis: The overexpression of HIF-1α confers better prognosis in clear cell type RCC (ccRCC). Furthermore, HIF-1α regulates other genes, specifically that of the carbon anhydrase IX (CA-IX), whose overexpression is practically only of the ccRCC and its determination is useful for this subtype. However, the involvement of the CA-IX has not been demonstrated in the prognosis or in the response to immunomodulators or antiangiogenics. Therefore, it is necessary to make a global evaluation of all this pathway: pVHL → HIF-1α → CA-IX, and even the analysis of other proteins and signaling pathways that also control the HIF-1α activity. In the latter case, the MAPK are critical in the HIF-1α activation, there being evidence on the experimental level of the control on its activity. although its clinical role as a biomarkers has not been established. Although the role of the MAPK in the phenomena of resistance to conventional chemotherapy and radiotherapy has been demonstrated, it has not been demonstrated in response to sorafenib, an important piece of information if we consider that it is an inhibitor of several protein kinases. Recently, it has been observed that the MAPK may be involved in the responses to different therapies, included those based on tyrosine kinase inhibitors. Conclusions: The confirmation of these data would suppose an explanation of the variation observed between patients who, with the same functional alteration of the vhl gene, have a different biological, clinical behavior and better selection of non-surgical therapies. © 2011 AEU. Published by Elsevier España S.L. All rights reserved.
Gonzalez M.J.,Centro Regional Of Investigaciones Biomedicas Crib |
Ruiz-Garcia A.,Centro Regional Of Investigaciones Biomedicas Crib |
Monsalve E.M.,Centro Regional Of Investigaciones Biomedicas Crib |
Sanchez-Prieto R.,Centro Regional Of Investigaciones Biomedicas Crib |
And 3 more authors.
European Journal of Immunology | Year: 2015
Delta-like protein 1 (DLK1) is a noncanonical ligand that inhibits NOTCH1 receptor activity and regulates multiple differentiation processes. In macrophages, NOTCH signaling increases TLR-induced expression of key pro-inflammatory mediators. We have investigated the role of DLK1 in macrophage activation and inflammation using Dlk1-deficient mice and Raw 264.7 cells overexpressing Dlk1. In the absence of Dlk1, NOTCH1 expression is increased and the activation of macrophages with TLR3 or TLR4 agonists leads to higher production of IFN-β and other pro-inflammatory cytokines, including TNF-α, IL-12, and IL-23. The expression of key proteins involved in IFN-β signaling, such as IRF3, IRF7, IRF1, or STAT1, as well as cRel, or RelB, which are responsible for the generation of IL-12 and IL-23, is enhanced in Dlk1 KO macrophages. Consistently, Dlk1 KO mice are more sensitive to LPS-induced endotoxic shock. These effects seem to be mediated through the modulation of NOTCH1 signaling. TLR4 activation reduces DLK1 expression, whereas increases NOTCH1 levels. In addition, DLK1 expression diminishes during differentiation of human U937 cells to macrophages. Overall, these results reveal a novel role for DLK1 as a regulator of NOTCH-mediated, pro-inflammatory macrophage activation, which could help to ensure a baseline level preventing constant tissue inflammation. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.